News

Aripiprazole linked to rare but serious compulsion problems


 

References

Rare but serious instances of impulse control problems have been reported in people taking the antipsychotic drug aripiprazole, according to a May 3 press release from the Food and Drug Administration.

Pathological gambling is listed as a side effect of aripiprazole (Abilify, Abilify Maintena, Aristada, and generics). Additional side effects seen in patients include compulsive eating, shopping, and sexual actions. The symptoms are rare but can affect anyone taking the medication and can result in serious harm to the patient.

Courtesy Wikimedia Commons/FitzColinGerald/Creative Commons License

All compulsive symptoms stopped when patients stopped taking aripiprazole or reduced their dosage. The FDA will add new warnings about the symptoms to all drug labels and patient medication guides.

“Health care professionals should make patients and caregivers aware of the risk of these uncontrollable urges when prescribing aripiprazole, and specifically ask patients about any new or increasing urges while they are being treated with aripiprazole. Closely monitor for new or worsening uncontrollable urges in patients at higher risk for impulse control problems,” the FDA said in the press release.

Find the full press release on the FDA website.

lfranki@frontlinemedcom.com

Recommended Reading

Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel
MDedge Psychiatry
Parkinson’s disease psychosis drug gets favorable review from FDA advisory panel
MDedge Psychiatry
Prepsychosis links with elevated metabolic syndrome
MDedge Psychiatry
Don’t assume that psychiatric patients lack capacity to make decisions about care
MDedge Psychiatry
Suicidal ideation: An 18-year-old male presents in crisis
MDedge Psychiatry
Suicidal ideation: Team-based care requires knowledge, resources
MDedge Psychiatry
Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?
MDedge Psychiatry
The doctor is sick
MDedge Psychiatry
APA guideline stresses judicious antipsychotics in dementia
MDedge Psychiatry
FDA approves first drug to treat hallucinations in Parkinson’s psychosis
MDedge Psychiatry